Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Sandra Brosda

University of Queensland

Australia

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Cell Biology

30%

Immunology

50%

Cancer Biology

100%

Epithelial-mesenchymal Transition

40%

Oncology

30%

Tumorigenesis

20%

Biomarker Research

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles15

Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma

Article Link

Year:

2024

Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy

Article Link

Year:

2024

C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients

Article Link

Year:

2023

Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy

Article Link

Year:

2023

The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank

Article Link

Year:

2023

Tumour microenvironment influences response to treatment in oesophageal adenocarcinoma

Article Link

Year:

2023

Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma

Article Link

Year:

2023

Elevation of fatty acid desaturase 2 in esophageal adenocarcinoma increases polyunsaturated lipids and may exacerbate bile acid‐induced DNA damage

Article Link

Year:

2022

ctDNA as a biomarker of progression in oesophageal adenocarcinoma

Article Link

Year:

2022

C5b-9 Membrane Attack Complex Formation and Extracellular Vesicle Shedding in Barrett’s Esophagus and Esophageal Adenocarcinoma

Article Link

Year:

2022

Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients

Article Link

Year:

2021

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

Article Link

Year:

2021

Complications and survival after hybrid and fully minimally invasive oesophagectomy

Article Link

Year:

2021

Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients

Article Link

Year:

2020

Baseline neutrophil–lymphocyte ratio holds no prognostic value for esophageal and junctional adenocarcinoma in patients treated with neoadjuvant chemotherapy

Article Link

Year:

2020

Collaborators11

Riccardo Dolcetti

Head, Clinical and Translational Immunotherapy

Peter MacCallum Cancer Centre

AUSTRALIA

Thomas Stoll

QIMR Berghofer Medical Research Institute

AUSTRALIA

Christos S. Karapetis

AUSTRALIA

Cameron Snell

Head of Anatomical Pathology

Peter MacCallum Cancer Centre

AUSTRALIA

Jessica Ng

AUSTRALIA

Wayne Phillips

Adjunct Professor

Monash Health

AUSTRALIA

Olga Kondrashova

Team Head, Molecular Oncology

QIMR Berghofer Medical Research Institute

AUSTRALIA

Kelly A Loffler

Flinders University

AUSTRALIA

Iain Thomson

University of Queensland

AUSTRALIA

Michelle M. Hill

The University of Queensland Diamantina Institute

AUSTRALIA

colm keane

Lab head

University of Queensland

AUSTRALIA

How do I reach out?

Meet Kite AI